亚临床心房动:抗凝还是不抗凝?
Sharath Kommu1,2, Param P Sharma3
1Department of Hospital Medicine, Marshfield Clinic Health System, Rice Lake, WI 54868, USA.
Journal of clinical medicine
|June 19, 2024
概括
亚临床心房动 (SCAF) 检测在新型监视器中很常见. 使用DOACs的抗凝固药可能会降低中风风险,但会增加出血,需要谨慎的患者-医生决策.
科学领域:
- 心脏病学 心脏病学
- 临床电生理学 临床电生理学
- 预防中风 预防中风
背景情况:
- 心房动 (AF) 增加了中风风险,通常需要抗凝药.
- 植入式/可穿戴式监视器经常检测到亚临床AF (SCAF) 或心房高频发作 (AHREs).
- 对SCAF抗凝剂的益处仍然不确定.
研究的目的:
- 评估SCAF患者抗凝血治疗的必要性.
- 分析最近的随机对照试验 (NOAH-AFNET 6,ARTESIA) 和它们关于SCAF治疗的元分析.
主要方法:
- 来自NOAH-AFNET 6和ARTESIA试验的数据的审查.
- 研究水平的元分析,结合试验数据.
- 评估中风风险的降低与抗凝血剂的主要出血风险的评估.
主要成果:
- 直接口服抗凝剂 (DOAC) 显著降低缺血性中风风险.
- DOACs可能会降低衰弱性中风的风险.
- 使用DOACs的抗凝固药与严重出血的风险增加有关.
结论:
- 在SCAF患者中,抗凝固药可以降低中风风险,但会增加出血风险.
- 共享决策至关重要,平衡中风预防的好处与出血风险.
- 个性化治疗策略对于管理SCAF患者至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Disturbances in Heart Rhythm
933
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
933
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
968
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
968
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735


